For personal use only

Transcription

1 Investor Presentation July 2011

2 DISCLAIMER This presentation is not and does not form part of any offer, invitation or recommendation in respect of securities. Any decision to buy or sell NuSep securities or other products should be made only after seeking appropriate financial advice. Reliance should not be placed on information or opinions contained in this presentation and subject only to any legal obligation to do so, the Company does not accept any obligation to correct or update them. This presentation does not take into consideration the investment objectives, financial situation or particular needs of any particular investor. To the fullest extent permitted by law, NuSep and its affiliates and their respective officers, directors, employees and agents, accept no responsibility for any information provided in this presentation, including any forward looking information, and disclaim and liability whatsoever (including for negligence) for any loss howsoever arising from any use of this presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this.

3 NuSep s Global Structure Germany NuSep Europe Atlanta NuSep, Inc. Singapore - NuSep Asia Sydney NuSep Holdings Ltd.

4 Corporate Structure Consumables Division Gels IQ Software Clinical Division IVF SpermSep Therapeutic Division PrIME Therapeutic Plasma Mini Mill

5 Board & Management BOARD John Manusu Executive Chairman Dr Hari Nair Managing Director Bill Spee Non Executive Director Iain Sorrell Non Executive Director MANAGEMENT Prakash Patel COO & Company Secretary Dr James Atwood GM US Dr John Andrews - CSO

6 NuSep s Technology Roadmap High Market Potential PrIME Fractionation SpermSep ProteoIQ nuview Clinical Division $110m Market Therapeutic Division $10B Market Consumables Division $200m Market Low Technology Shift NuSep s Vision - To be the Premier Technology Supplier in the BioSeparations Market

7 nuview Gels The Market US$150 million pa Global market: US (45%), Europe (40%), Other (15%) 60% of the market use pre-made gels NuSep has <1% market share Two Competitors own 95% of the US Gels Market: Invitrogen Bio-Rad NuSep s Gels now compatible with both Invitrogen & Bio-Rad tanks Bio-Rad 50% Invitrogen 45% 6,000,000 Bio-Rad & Invitrogen Gels Sold In the US Every Year nuview Gels are Best in Class Other 5%

8 ProteoIQ The Market US$130m pa global market and relatively untapped (10,000 labs) US (50%) & Europe (25%) Product Lifecycle Intro Growth Maturity Decline Data analysis is major bottle-neck restricting proteomics research Users spend weeks analysing data ProteoIQ software processes this data in hours US sales accelerating post: Release of Version 2.2 Annual License Market in early growth phase

9 ProteoIQ - Best in Class ProteoIQ - the Google for proteins MaxQuant Free SILAC ProteoIQ - $12,600 (V2.2) Label Free SILAC itraq/tmt Non-Linear Dynamics Progenisis - $28,000 Label Free Quant Proteome Software - Scaffold $8,000 ($2,000 annual) itraq/tmt, Spectral Counting AB Sciex Protein Pilot $30,000 ($10,000 annual) itraq/tmt Only AB instruments

10 Consumables Summary Gels & IQ are Best in Class Distribution is the key to sales growth Signed $850k Distribution Agreement with Thermo Signed 3 new Asian Distributors A Cash Cow to fund the Other Divisions

11 SpermSep IVF SpermSep Market $110m worldwide $5m Australian IVF SpermSep market

12 SpermSep Summary A Product Developed by Clinicians Successful Clinical Trial in 2008 with 3 live births from 9 women New Cartridge Patent lodged $1m to Fund Final Clinical trial from 15 Options in March 2012 Market Launch Late 2012 Australian Market $5m pa No Commercial Competition Applications in the veterinary field

13 NuSep Plasma Fractionation 2010 Blue Sky 2011 Now Reality

14 The Blood Plasma Market $US10 billion market worldwide, Dominated by 5 fractionators NuSep is focused on the $US1billion Niche Asian market Most Asian Countries Waste over 50% of their plasma NuSep can process this Currently Unprocessable Plasma This: Saves $10m - $100m per Country per year Enables these countries to become self sufficient NuSep is focused on a niche market - Asian countries that want to process their Currently Unprocessable Plasma.

15 Plasma - the Liquid Gold US$100 Barrel US $120 Litre

16 The Numbers Supplier CSL Ltd Baxter Healthcare Pty Ltd Wyeth Australia Pty Ltd Novo Nordisk Pharmaceuticals Pty Ltd Products Purchased Plasma products albumin products immunoglobulin products (including IVIg and hyperimmune products) plasma-derived clotting factors Diagnostic reagent products blood grouping sera reagent red cell products Imported Blood Products Factors XI and XIII IVIg standing offer Imported Blood Products Recombinant Factor VIII Protein C Factor VII concentrate Factor Eight inhibitor Bypass Agent (FEIBA) WinRho Imported Blood Products Recombinant Factor VIII Recombinant Factor IX Imported Blood Products Recombinant Factor VIIIa ($M) ($M) Australia Spends ~$400m pa on Plasma Products with a Population of 22m Singapore has a population of 5m Malaysia has a population of 25m Thailand has a population of 65m Philippines has a population of 90m Octapharma Pty Ltd Imported Blood Products IVIg Standing Offer TOTAL Source: National Blood Authority Australia Annual Report

17 PrIME - the Key to The Liquid Gold Current Technology PrIME Technology Process Currently Unprocessable Plasma Double the final product yield Process small volumes Disposable production process Produce new products Increase product safety Reduce process time

18 Mini Mill Business Model Starts in Singapore

19 Steps to Success Unique Selling Proposition Ability to process small volumes Ability to process Currently Unprocessable Plasma Government Support Singapore EDB Financial Funding Agreed to Clinical trial in Singapore Pharmaceutical Industry Support LOI from Philippine based United Laboratories

20 PrIME Timeline Build out of Manufacturing facility (9-12 months) Manufacture initial production batches of IVIG and Albumin. (12 months) Complete clinical trials of the IVIG and Albumin in Singapore. (24 months) Pursue expansion into additional Asian markets FEED* report Site selection Gain HSA approval for NuSep Asia s manufacturing facility. (12 months) First sales of IVIG and Albumin in Singapore. (24 months) -Thailand - Indonesia - China - India - Malaysia - Philippines EDB Funding & Support LOI Philippines *Front End Engineering Design

21 PrIME Singapore Budget S$M S$M S$M S$M S$M S$M S$M Sales - - $4.75 $11.5 $24.5 $32.7 $36 Gross Profit ($0.5) ($0.3) $3.3 $8.3 $17.6 $23.9 $26.4 EBITDA ($2.7) ($2.8) $1.0 $5.5 $14.8 $21 $23.5 NPAT ($2.8) ($3) $0.5 $4.9 $11.8 $16.9 $19 Budget is in Singapore dollars. 1 S$ = A$.76

22 Recent Achievements Select the Singapore Tech View Facility Employ Director GMP Operations & Director Regulatory Affairs Sign Plasma Supply Agreement Receive Singapore Government Funding & Support LOI from Philippine based United Laboratories Discussions with other Asian Countries

23 Conclusion Consumables Business (Gels/IQ) is Profitable $1m investment required to complete the SpermSep Locked in via March 2012 Share Options The PrIME Mini Mill is Game Changing Singapore validates the PrIME Mini Mill and now has Singapore Government & Industry Support

24